In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
Search results for: baricitinib
Long-Term Safety of Baricitinib for RA
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2
The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.
Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market
Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…
Baricitinib: Early vs. Late Treatment Outcomes in RA Patients
Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
The Rescue: Moving RA Patients from Adalimumab to Baricitinib
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
Long-Term Data Show Baricitinib Is Safe & Effective for RA
Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…
Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
FDA Approves Baricitinib for RA Patients
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine
The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…
- 1
- 2
- 3
- …
- 10
- Next Page »